RecruitingPhase 1NCT07598370

A Study of LY3439539 in Participants With Alzheimer's Disease

A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Following Treatment With LY3439539 in Participants With Symptomatic Alzheimer's Disease

Sponsor

Eli Lilly and Company

Enrollment

30 participants

Start Date

May 21, 2026

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease

Summary

The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease. Participation in the study will last approximately 9 months with visits about once a month.

Eligibility

Min Age: 50 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called LY3439539 for people with alzheimer disease. The study is currently recruiting participants at 7 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLY3439539

Administered IV

Locations(9)

Irvine Clinical Research

Irvine, California, United States

Flinders Medical Centre

Adelaide, Australia

University of the Sunshine Coast Clinical Trial Centre

Birtinya, Australia

Austin Health - Heidelberg Repatriation Hospital

Ivanhoe, Australia

Southern Neurology

Kogarah, Australia

Macquarie University Hospital

Macquarie University, Australia

The Alfred

Melbourne, Australia

New Zealand Brain Research Institute

Christchurch, New Zealand

Lilly Centre for Clinical Pharmacology

Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07598370

Related Trials

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787292 locations

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229258 locations